Dr. Yaron Werber is a Managing Director and senior research analyst on Cowen’s biotechnology team. In this role, Dr. Werber is responsible for providing analysis on large-, mid-, and small-cap biotechnology stocks. Dr. Werber has 18 years of experience as a research analyst in the financial services industry and has served as an executive in a public biotechnology company.
Prior to rejoining Cowen, Dr. Werber was a founding team member, chief business and financial officer, treasurer and secretary of Ovid Therapeutics, a biotechnology company focused on developing transformative drugs for orphan disorders of the brain.
Prior to joining Ovid, Dr. Werber worked at Citi from 2004 to 2015, where he most recently served as a managing director and head of U.S. healthcare and biotech equity research. Previously, Dr. Werber was a senior biotech analyst and vice president at SG Cowen Securities Corporation from 2001- 2004.
Dr. Werber has been awarded several accolades for performance and stock picking, he has been highly ranked by Institutional Investor magazine, has received awards from Starmine and was voted among the top five analysts in biotech in the Wall Street Journal’s “Best on the Street” Greenwich survey. In 2017, Dr. Werber was selected as an “Emerging Pharma Leader” by Pharmaceutical Executive magazine. He has frequently been featured as a guest on CNBC, Fox News, Bloomberg News and has been quoted in the Wall Street Journal, New York Times, Fortune, Forbes, Bloomberg thestreet.com and BioCentury.
Dr. Werber earned his B.S. in Biology from Tufts University, cum laude, and a combined M.D./MBA degree from Tufts University School of Medicine where he was a Terner Scholar.